{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-045420","form_type":"8-K","ticker":"RBOT","cik":"0001812173","company_name":"Vicarious Surgical Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.127431+00:00","generated_at":"2026-06-24T02:59:31.406130+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vicarious Surgical Q2 2022: adjusted net loss $19.1M, operating expenses up 189% YoY","bullets":["Operating expenses of $19.1M for Q2 2022, up from $6.6M in Q2 2021; R&D $10.1M, G&A $7.8M, S&M $1.3M.","Adjusted net loss of $19.1M ($0.16 loss per share) vs $6.6M ($0.08 loss per share) prior year.","GAAP net loss of $1.5M ($0.01 loss per share) vs $6.6M ($0.08 loss per share) prior year.","Cash burn rate for Q2 2022 was $15.7M; no revenue reported (pre-commercial stage).","Beta 2 system development ongoing; announced Center of Excellence partnerships with UH Ventures and HCA Healthcare."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-045420","json":"https://secwatch.observer/filing/0001213900-22-045420.json","markdown":"https://secwatch.observer/filing/0001213900-22-045420.md","text":"https://secwatch.observer/filing/0001213900-22-045420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812173/000121390022045420/0001213900-22-045420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812173/000121390022045420/ea163898-8k_vicarious.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:59:31.406130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}